People with myasthenia gravis (MG) often experience mental health struggles, but their lives are also full of gratitude and hope — and these positive and negative emotions don’t cancel each other out, but rather coexist separately. That’s according to results from a survey conducted by Bionews, the parent company…
News
Lily Sander will never forget what it was like to meet other people with neuromuscular diseases the first time she attended Muscular Dystrophy Association (MDA) Summer Camp. Living with Charcot-Marie-Tooth disease, Sander had met only one or two other people with neuromuscular diseases in her city. She was…
Approved and experimental targeted treatments for generalized myasthenia gravis (gMG) show different patterns of benefit across measures of treatment response, according to an indirect comparison analysis of clinical trial data. Using mathematical models to account for differences in dosing schedules, researchers found that individual therapies differed in their maximum…
A new study comparing outcomes of two different strategies for treating generalized myasthenia gravis (gMG) found that both the approved med Vyvgart (efgartigimod alfa) and a blood-cleaning procedure called double-filtration plasmapheresis (DFPP) were generally equally effective in easing symptoms. Both treatments significantly reduced disease-causing antibodies and improved daily…
A small clinical trial found early signs that Cabaletta Bio’s experimental CAR T-cell therapy rese-cel (resecabtagene autoleucel) may safely ease symptoms for adults with generalized myasthenia gravis (gMG). That’s according to data from the U.S.-based Phase 1/2 RESET-MG trial (NCT06359041), in which participants with different types of…
More than 90% of people with generalized myasthenia gravis (gMG) treated with telitacicept for about a year achieved deep reductions in symptom severity, with more than 40% showing minimal symptoms that had little to no impact on daily life. That’s according to new data from a China-based Phase…
A second round of Descartes-08, Cartesian Therapeutics’ experimental CAR T-cell therapy, may allow some people with generalized myasthenia gravis (gMG) to sustain clinically meaningful symptom reduction, according to data from a clinical trial. James F. Howard Jr., MD, a trial investigator and University of North Carolina School of…
For many people living with rare neuromuscular diseases, the most meaningful part of a recent Chicago gathering was not just the medical updates — it was finding a community that understood their daily struggles. The realization that they were not alone set the tone for MDA Engage: Chicago, a…
Regeneron Pharmaceuticals’ investigational therapy cemdisiran significantly reduced hospitalization rates among people with generalized myasthenia gravis (gMG) in a global clinical trial. The data from the Phase 3 NIMBLE study (NCT05070858) were presented by trial investigator Ali Habib, MD, a neurologist at the University of California, Irvine, at…
A single dose of Kyverna Therapeutics’ experimental CAR T-cell therapy mivocabtagene autoleucel (miv-cel) led to reductions in symptom severity among people with difficult-to-treat generalized myasthenia gravis (gMG) that have been sustained for up to 1.5 years. Importantly, most participants reached a state where their gMG symptoms have…
Recent Posts
- How an MG diagnosis changed our lives forever
- Bionews survey finds positive and negative emotions coexist in MG
- MDA Engage: National ambassador brings message of belonging, resilience
- gMG treatments show varied benefits across response measures
- Like a donkey, my MG body is stubborn, but it has also carried me